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Cells possess multiple mechanisms that protect
against the accumulation of toxic aggregation-prone
proteins. Here, we identify a pre-emptive pathway
that reduces synthesis of membrane proteins that
have failed to properly assemble in the endoplasmic
reticulum (ER). We show that loss of the ER
membrane complex (EMC) or mutation of the Sec61
translocon causes reduced synthesis of misfolded
forms of the yeast ABC transporter Yor1. Synthesis
defects are rescued by various ribosomal mutations,
as well as by reducing cellular ribosome abundance.
Genetic and biochemical evidence point to a
ribosome-associated quality-control pathway trig-
gered by ribosome collisions when membrane
domain insertion and/or folding fails. In support of
this model, translation initiation also contributes to
synthesis defects, likely by modulating ribosome
abundance on the message. Examination of transla-
tion efficiency across the yeast membrane proteome
revealed that polytopic membrane proteins have
relatively low ribosome abundance, providing evi-
dence for translational tuning to balance protein syn-
thesis and folding. We propose that by modulating
translation rates of poorly folded proteins, cells can
pre-emptively protect themselves from potentially
toxic aberrant transmembrane proteins.
INTRODUCTION
Integral membrane proteins employ multiple machineries to
facilitate correct targeting and membrane insertion [1]. The
signal recognition particle binds the initial transmembrane
domain (TMD) on the ribosome to deliver the nascent protein
to the endoplasmic reticulum (ER) [2]. Membrane insertion is
achieved via translocation channels, most commonly via the
Sec61 translocon [1]. Subsequent folding of TMDs within the
constraint of a planar membrane presents some uniqueCurrent Biology 30, 1–11, March 9, 2020 ª 2020
This is an open access article undproblems. For example, TMDs often contain polar residues
that comprise a hydrophilic surface in the final structure, but
these residues are thermodynamically unfavorable in the context
of individual TMDswithin the lipid bilayer [3]. Moreover, folding of
some TMDs is necessarily post-translational. ATP-binding
cassette (ABC) transporters, with 12 TMDs that form a mem-
brane-embedded channel, acquire a domain-swapped confor-
mation whereby early-emerging TMDs pack against later
TMDs [4]. Thus, folding cannot proceed in a linear manner as in-
dividual TMDs emerge into the lipid bilayer. TMD-folding require-
ments could explain why some ABC transporters, like human
CFTR, have a poor synthesis yield [5] despite efficient co-trans-
lational folding of their cytosolic domains [6]. Finally, nascent
proteins must avoid ER-associated degradation (ERAD), which
targets misfolded proteins for ubiquitination and proteasomal
degradation. Protective chaperones, or holdases [7], for TMD-
containing proteins have not been described mechanistically
but have been proposed to protect nascent membrane proteins
that undergo post-translational folding [8]. Thus, despite reason-
able understanding of TMD handling during targeting and inser-
tion [1], howmembrane proteins navigate this pathway to folding
completion remains unclear.
The yeast ABC transporter Yor1 serves as a tractable model
for biogenesis of polytopic membrane proteins. Yor1 is a pleio-
tropic drug pump that confers resistance to the mitochondrial
poison oligomycin [9]. Yor1-DF670 is a misfolded mutant, analo-
gous to human CFTR-DF508, which is a causative allele in cystic
fibrosis patients [10]. The DF mutation renders the protein sub-
ject to ERAD [11], in the case of Yor1 thereby conferring oligomy-
cin sensitivity to cells [12, 13]. We previously surveyed the yeast
genome for components that influence the functional expression
of Yor1-DF [14]. Our screen identified the yeast ER membrane
complex (EMC) [15] as a biogenesis factor that promotes the
functionality of Yor1-DF, and we demonstrated a similar role
for human EMC in CFTR stability [14]. The EMC is a conserved
protein complex implicated broadly in polytopic membrane-pro-
tein biogenesis [8] and mechanistically in TMD insertion at the
ER [2, 16]. Deletion of Sop4, also known as Emc7, caused
reduced synthesis of Yor1-DF inmetabolic labeling experiments,
consistent with an early role in ER targeting, insertion, and/or
folding [14].MRC Laboratory of Molecular Biology. Published by Elsevier Ltd. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Biosynthetic Defects in Yor1-DF
upon Loss of EMC Function
(A) Yor1-DF(HA) was immunoprecipitated after
metabolic labeling of WT and emc7D cells for the
indicated times. The emc7D strain showed
reduced incorporation for Yor1-DF(HA) over all
time points. n = 22 (WT) and 16 (emc7D); error bars
depict SEM.
(B) Radiolabeled Yor1-DF(HA) was immunopre-
cipitated from the deletion strains indicated; loss of
EMC2 and/or EMC6 resulted in reduced incorpo-
ration at t = 10 in relation to WT.
(C) Yor1-DF(HA), Gap1, and Sec22 were immu-
noprecipitated from WT and emc7D strains after
metabolic labeling for the indicated times; only
Yor1-DF showed reduced incorporation at t = 10 in
relation to WT.
(D) Synthesis of misfolded Ycf1 and Ste6 was
quantified in WT and emc7D strains revealing no
effect of loss of Emc7.
Statistical analyses used an unpaired Student’s
t test; error bars depict SD (B), (C), and (D). See
also Figure S1.
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Yor1-DF biogenesis and describe additional mechanisms that
impact synthesis of Yor1. We find that defects in Yor1 folding
and membrane insertion result in reduced protein synthesis.
Genetic, biochemical, and bioinformatic experiments suggest a
co-translational mechanism driven by ribosome function and
abundance. We propose that ribosome occupancy is an impor-
tant determinant of biosynthesis of membrane proteins, with
high ribosome density associated with poor outcomes, perhaps
caused by ribosome collisions. Cells could thus use translational
tuning to modulate membrane-protein synthesis, deploying a
pre-emptive quality-control checkpoint that protects the integ-
rity of the secretome.
RESULTS
To explore the basis for reduced Yor1-DF synthesis in emc7D
cells, we tested the kinetics of protein synthesis using metabolic
labeling experiments. We observed a rapid plateau in 35S-Met/
Cys incorporation into Yor1-DF(HA) in the emc7D strain, greatly
reduced in relation to wild type (WT), that was not resolved at
increasing time points (Figure 1A). Thus, loss of Emc7 impacts
the earliest stages of Yor1-DF synthesis. Because all members
of the EMC were deletion enhancers of Yor1-DF function [14],2 Current Biology 30, 1–11, March 9, 2020we tested whether each EMC mutant
showed similar synthesis defects. Indeed,
Yor1-DF synthesis was attenuated in
emc2D and emc6D mutants, an effect
that was exacerbated in an emc2D
emc6D double mutant (Figure 1B). This
phenotypemirrored oligomycin sensitivity
conferred by EMC deletions, with emc2D,
emc6D and emc7D the most sensitive
(Figure S1A). These growth assays use
low concentrations of oligomycin such
that Yor1-DF in a wild-type cell confersmodest resistance, revealing growth defects when biogenesis
factors are deleted [14]. Loss of mammalian Emc2 or Emc6 de-
stabilizes the entire EMC [2, 17], perhaps explaining their signif-
icant impact in our system.
We next tested whether Yor1-DF synthesis defects reflect
global changes in membrane-protein biosynthesis. Synthesis
of the polytopic membrane protein Gap1 and the tail-anchored
protein Sec22 were not reduced in the emc7Dmutant, suggest-
ing a specific rather than universal response (Figure 1C).
Similarly, two other misfolded ABC transporters, Ycf1-DF and
Ste6-166, were synthesized normally in the emc7D strain (Fig-
ure 1D), suggesting a surprising level of client specificity. Consis-
tent with specific translational effects, emc7D cells did not have
elevated phosphorylated eIF2a even when Yor1-DF was ex-
pressed (Figure S1B), suggesting that the integrated stress
response is not responsible for attenuated Yor1 synthesis.
The substrate selectivity of synthesis defects, coupled with
our previous observation that loss of EMC impacts Yor1-DF
but notwild-type Yor1 [14], suggests that specific folding defects
trigger reduced biosynthesis. We investigated how distinct mis-
folding lesions impact EMC-dependent oligomycin sensitivity by
using a panel of Yor1 alleles that affect folding and trafficking to
different degrees (Figure 2A). If oligomycin sensitivity results
from early quality control triggered by the combination of Yor1-
Figure 2. EMC-Dependent Synthesis De-
fects Correlate with Specific Sites of Yor1
Misfolding
(A) Cartoon of Yor1, showing relevant folding and
trafficking mutations. ICL, intracellular loop; NBD,
nucleotide binding domain.
(B) Serial dilutions of yor1D or yor1D emc7D strains
expressing the indicated alleles of YOR1 were
spotted onto YPEG media with and without oligo-
mycin. Emc7-associated oligomycin sensitivity
correlated with misfolding defects that occurred
early in the protein sequence.
(C) Metabolic labeling of the indicated Yor1 alleles
in wild-type or emc7D mutants was quantified at
t = 5 min and normalized to WT; synthesis defects
phenocopied oligomycin sensitivity.
Statistical analysis was an unpaired Student’s t
test; error bars depict SD.
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folding to Yor1-DF or cause minimal folding defects should be
unaffected by EMC loss. The DF mutation, in the middle of the
protein, profoundly impacts packing of transmembrane helices,
probably by perturbing the interface between the intracellular
loop (ICL) and the nucleotide binding domain (NBD), which
drives the global fold [13, 18]. Two intragenic suppressing muta-
tions, F270M and S1168M, restore folding to Yor1-DF and other
misfolded alleles [18]. If the folding state of the nascent protein
drives early quality control, then stabilization of the fold should
diminish the effects of EMC loss. Indeed, the Yor1-DF/F270S/
R1168M mutant was less affected by loss of EMC7 than was
Yor1-DF (Figure 2B). Two mutations in the N-terminal region, in
ICLs 1 and 2, respectively, have different degrees of misfolding;
the G278R mutation in ICL1 is profoundly misfolded and ER re-
tained [18], whereas R387G in ICL2 is a functional mutation that
causes partial misfolding [19]. These alleles were differentially
affected by EMC7 deletion; oligomycin sensitivity of the ICL1
mutant was enhanced in an emc7D strain, whereas the ICL2
mutant was unaffected (Figure 2B). Finally, I1084P in ICL4, which
yields a profoundly misfolded protein [18], was unaffected by
loss of EMC7 (Figure 2B). In the context of the folding landscapeof Yor1, the late emergence of the ICL4
lesion during synthesis apparently ren-
ders the protein less dependent on
EMC, suggesting EMC acts upstream of
the eleventh TMD. Finally, a trafficking
mutant, Yor1-D71A/E73A, which is
correctly folded but fails to engage ER
export machinery [13], was unaffected
by EMC7 deletion even at high oligomycin
concentrations (Figure 2B). Oligomycin
phenotypes corresponded to in vivo syn-
thesis defects in pulse-labeling experi-
ments; Yor1-G278R showed reduced syn-
thesis in the emc7D strain, whereas Yor1-
R387G and Yor1-I1084P were unaffected
(Figure 2C). We conclude that the folding
state of the client protein is a driver of
quality control triggered by loss of EMC,and the location and severity of the misfolding lesion are impor-
tant determinants. These results partially explain the client spec-
ificity we observed among ABC transporters; the Ste6misfolding
lesion occurs late in the protein, likely downstream of a putative
site of EMC action. For Ycf1, the presence of numerous addi-
tional upstreamTMDs prior to the first nucleotide binding domain
might alter EMC positional requirements [20].
Having identified folding specificity in Emc7-dependent biogen-
esis defects,we sought to understand the fateofmisfoldedYor1 in
theabsenceofEMC function.Our labelingassaysuseC-terminally
tagged Yor1-DF; antibodies raised against the N-terminal cyto-
solic domain, and attempts to epitope tag Yor1 at the N terminus,
failed in immunoprecipitation (IP) experiments; thus, translation
and degradation intermediates are not detectable. We first
confirmed that protein turnover was unaffected by loss of EMC7
(Figure 3A) [14], consistent with a biogenesis defect rather than
degradation after complete synthesis. We then asked whether
ERAD disposes of aberrant Yor1-DF during the time frame of our
experiments. We chose two ERAD-related mutants, rpn4D and
cue1D, that were moderate deletion suppressors and stabilized
Yor1-DF [14]. We tested Yor1-DF pulse-labeling in emc7D rpn4D
and emc7D cue1D mutants. Although deletion of neither RPN4Current Biology 30, 1–11, March 9, 2020 3
Figure 3. Yor1-DF Synthesis Defects Reflect Ribosome-Associated Events
(A) Degradation of Yor1-DF(HA) was similar in WT and emc7D cells after a 10 min pulse and chase times indicated; n = 2.
(B) Deletion of ERAD factors RPN4 and CUE1 in the emc7D background did not restore labeling of Yor1-DF(HA) in relation to WT at t = 10 min.
(C) Deletion of the ribosomal proteins indicated reversed the effect of EMC7 deletion on metabolic labeling of Yor1-DF(HA), normalized to WT at t = 10 min.
(D) Serial dilutions of the indicated strains expressing Yor1-DF were spotted onto YPEG media supplemented with oligomycin. The emc7D strain showed
enhanced oligomycin sensitivity; additional deletion of ribosomal proteins reversed this effect.
(E) Oligomycin resistance of the indicated strains expressing Yor1-DF was assessed by serial dilution; deletion of HEL2, DOM34, and SLH1 restored partial
oligomycin resistance, whereas deletion of LTN1 had no effect.
(F) Yor1-DF(HA) synthesis was measured in the indicated strains and normalized to WT. Deletion of HEL2 restored Yor1-DF(HA) synthesis, whereas deletion of
LTN1 had no effect.
Statistical tests were unpaired Student’s t test; error bars depict SD. See also Figures S2, S3, and S4.
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(Figure 3B), rpn4D and cue1D single mutants also showed
reduced Yor1-DF synthesis at early time points, albeit to a lesser
extent (Figure S2A), rendering the data difficult to interpret.
Attempts to inhibit ERAD by chemical means were unsuccessful
because of small-molecule induction of Yor1 transcription (data
not shown).
To probe whether EMC loss exacerbates folding defects that
might trigger ERAD, we tested the folding state of Yor1-DF
with limited proteolysis [13]. Protease susceptibility of Yor1-DF
was unchanged betweenWT and emc7D cells (Figure S2B), sug-
gesting no differences in global fold of the nascent protein.
Furthermore, labeled cell lysates fractionated into soluble and
insoluble fractions showed no difference between WT and
emc7D strains (Figure S2C), suggesting that protein aggregation4 Current Biology 30, 1–11, March 9, 2020is not responsible for the observed phenotypes. Similarly, Yor1-
DF-GFP did not accumulate in large foci (Figure S2D; compare
with Figure 4B, middle panel), demonstrating that Yor1-DF is
unlikely to form insoluble aggregates that are refractory to IP.
These data collectively argue that global folding of Yor1-DF is
not altered in the absence of Emc7.
Although unable to definitively exclude contributions from
ERAD, we note that the time frame of the defects that we observe
is more consistent with co-translational events rather than with a
post-translational process. To further explore potential co-transla-
tional regulators, we returned to our original screen, finding signif-
icant enrichment for proteins involved in cytoplasmic translation,
nonsense-mediated mRNA decay, and ribosome assembly as
suppressors of oligomycin sensitivity associated with Yor1-DF
(Figure S3). We validated a subset of ribosomal mutants for their
Figure 4. Sec61 Dysfunction Phenocopies
EMC7 Deletion to Trigger Biosynthetic De-
fects
(A) Metabolic labeling experiments revealed syn-
thesis defects for both WT Yor1 and Yor1-DF in an
ER-targeting mutant, sec61-R275E/K464E/K470E,
whereas a TMD-gating mutant, sec61-R275E/
R406E, caused reduced synthesis only of Yor1-
DF(HA), and a post-translational mutant, sec61-
N302L, was unaffected. Labeling was quantified at
t = 5 and normalized to a SEC61+ strain.
(B) Fluorescence microscopy of WT and mutant
cells expressing Yor1-DF-GFP revealed ER local-
ization in WT and sec61-R275E/R406E cells but
punctate accumulation in the sec61-R275E/K464E/
K470E mutant.
(C) Deletion of HEL2 restored Yor1-DF(HA)
synthesis in the sec61-R275E/R406E strain.
(D) Steady-state levels of Yor1-DF(HA) mRNA in
the strains indicated were quantified by qPCR and
normalized to that of actin with a standard curve.
(E) Yor1-DF synthesis was measured in an emc7D
sec61D ssh1D strain expressing either SEC61 or
sec61- Q129N, a permissive gating mutant, which
did not reverse the synthesis defects associated
with loss of Emc7.
Statistical tests were unpaired Student’s t test and
reflect the difference between the strains indicated
and a WT strain; error bars depict SD.
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of Yor1-DF defects in both pulse labeling (Figure 3C) and pheno-
typic assays (Figure 3D). Ribosomal mutants can impact multiple
aspects of protein biogenesis, including ribosome assembly,
translation initiation and elongation, and ribosome-associated
quality control (RQC). Of the mutants that we tested, Rpl12 likely
improves the folding yield of Yor1-DF at least in part by reducing
elongation rates, as has been demonstrated for human CFTR [21,
22]. In contrast, Rps9 contributes to an interface between collided
ribosomes [23], after ribosome stalls. The interface creates a plat-
form for ribosome ubiquitination and subsequent engagement of
mRNA decay and RQC pathways [24–26]. In the context of
Yor1-DF biogenesis, absence of Rps9might reduce the efficiency
of ribosome ubiquitination and thereby permit time for stall resolu-
tion. Finally, Rps0 participates in translation initiation [24] [25], de-
fects in which would reduce ribosome occupancy along anmRNA
and thus reduce the chance of ribosome collisions. Moreover,
Rps0 also contributes to ribosomal small subunit maturation[26], which could also influence total ribo-
some abundance. Therefore, ribosome
function, abundance, and translational dy-
namics seem to be important factors in
Yor1-DF biogenesis.
We further explored the model of colli-
sion-driven quality control by testing cyto-
plasmic RQC mutants for effects on Yor1-
DF synthesis [27]. Deletion of genes up-
stream of the committed step in RQC
rescued theemc7Doligomycinphenotype,
whereas deletion of the downstream E3
ligase Ltn1 had minimal effect (Figure 3E).Lack of rescue by ltn1D is consistent with its late role in degrada-
tion of the truncated nascent chain after ribosome splitting [27], at
which point protein synthesis to completion of translation is no
longer possible. In contrast, abrogation of factors that act prior
to ribosome splitting (e.g., Hel2, Dom34, and Slh1 [28, 29]) can
permit stalls to be overcome and protein synthesis to progress
[30]. Indeed, in pulse-labeling experiments in emc7D hel2D and
emc7D ltn1D strains, we see robust rescue in the hel2D back-
ground but not in the ltn1D condition (Figure 3F). Together, these
findings are consistent with a role for RQC when Yor1-DF fails to
properly integrate or fold. Whether all features of RQC, including
C-terminal Ala- and Thr-extension (CAT-tailing) of the nascent
chain [31], are fulfilled in this system remains to be tested. More-
over, we note that some of the rescue effects we observe are
modest in relation to the robust rescue observed with ribosomal
mutants, suggestive of multiple quality-control outcomes.
RQC components that drive ribosome splitting and recycling
also participate in mRNA surveillance, including nonsense-Current Biology 30, 1–11, March 9, 2020 5
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combined with genetic effects of loss of the Ski complex, which
mediates mRNA degradation (Figure S3), led us to check
whether Yor1 mRNA was reduced in conditions where EMC
loss triggers RQC. We measured steady-state levels of mRNA
for different Yor1 alleles and found only a modest reduction in
mRNA levels for the Yor1-G278R (ICL1) mutant in emc7D cells
(Figure S4). Given genetic evidence for involvement of the SKI
complex in Yor1-DF function (Figure S3; [14]), the lack of
mRNA degradation is somewhat surprising but highlights that
the synthesis defects we observe are predominantly influenced
by co-translational events.
Because the EMC has recently been defined as a membrane-
domain insertase [2, 16], we next tested whether defects in
canonical translocation phenocopy loss of EMC and trigger
RQC. We examined Yor1 biogenesis in Sec61 mutants that are
defective in ER targeting and insertion. We tested three Sec61
gatingmutants with a sec61D ssh1D double-mutant background
to avoid redundant handling by alternative translocons [33, 34].
The sec61-R275E/K464E/K470E mutant that is defective for co-
translational protein insertion and ribosome binding [33] showed
decreased synthesis of both WT Yor1 and Yor1-DF (Figure 4A).
This defect likely stems from initial targeting failure because
Yor1-DF-GFP accumulated in large intracellular puncta that
probably correspond to insoluble aggregates (Figure 4B).
Conversely, sec61-R275E/R406E, which is also impaired in co-
translational targeting [33], showed selective synthesis defects
for Yor1-DF; WT Yor1 was unaffected (Figure 4A). In this mutant,
Yor1-DF showed a normal ER distribution, arguing against
formation of insoluble aggregates (Figure 4B). Finally, sec61-
N302L, which selectively impacts post-translational protein inser-
tion [34], showed no synthesis defects (Figure 4A).
We next tested whether Sec61 dysfunction also triggers RQC
and found that Yor1-DF synthesis defects in the sec61- R275E/
R406E background were reversed by deletion of Hel2 (Figure 4C).
Moreover, steady-state Yor1-DF mRNA levels were reduced in
the sec61- R275E/R406E mutant, and this effect was reversed
by deletion of HEL2 (Figure 4D), suggesting that RQC triggered
by Sec61 dysfunction also causes mRNA degradation. Given
the similarities with respect to Yor1 synthesis in the sec61-
R275E/R406E and emc7D mutants, we reasoned that more
promiscuous handling of Yor1 TMDs by Sec61 might bypass
the need for EMC.We therefore tested if EMC loss could be sup-
pressed by a permissive gating mutant of Sec61, sec61-Q129N,
which accepts poorly hydrophobic signals that are not normally
recognized by the translocon [34]. This permissive condition
could not replace Emc7 function in Yor1-DF biogenesis
(Figure 4E), suggesting that EMC, like Sec61, acts early in Yor1
synthesis but is functionally distinct.
Together, our findings suggest a co-translational protein qual-
ity-control pathway that is influenced by: (1) nascent protein
folding state; and (2) function of ER insertion machinery and/or
TMD chaperones. We propose that hydrophobic TMDs can
cause transient ribosomal stalls that are overcome either by
productive folding or EMC action (Figure 5A, left panel). EMC
abrogation, combined with folding defects, prolongs stalls that
in turn trigger RQC, perhaps via ribosome collisions (Figure 5A,
right panel). We searched for evidence of ribosome collisions
by using yeast mutants that lack Hel2-mediated ubiquitination6 Current Biology 30, 1–11, March 9, 2020sites [29], finding modest rescue of the emc7D synthesis defect
in a rps20-K6R/K8R mutant but not in the rps3-K212R back-
ground (Figure 5B). Such specificity has previously been
observed for RQC of multiple translation-arrest models [29]
and places Rps20 ubiquitination at a critical juncture for detec-
tion of stalls and triggering of RQC. Rps20, also known as
uS10 and an essential gene in yeast, lies at the disome interface
that probably corresponds to the recognition event that triggers
initiation of RQC [23, 24].
Consistent with a model of collision-driven quality control for
Yor1-DF, our original screen revealed multiple ribosome assem-
bly factors as deletion suppressors [14]. Rrp6, a subunit of the
nuclear exosome that processes ribosomal RNA, was among
the strongest Yor1-DF suppressors (Figure S3). Deletion of
RRP6 reversed the oligomycin sensitivity of an emc7D strain
(Figure 5C), suggesting that reducing ribosome abundance res-
cues co-translational biogenesis defects. We confirmed that the
rrp6D mutant has fewer 80S ribosomes and polysomes (Fig-
ure S5A), as previously reported [35]. Because Yor1 undergoes
co-translational targeting to the ER, it seems likely that potential
collision events occur on ER-engaged ribosomes. We therefore
tested whether ER expansion might reduce ribosome collisions
and thereby suppress EMC loss. Deletion of the lipid synthesis
regulator, OPI1, causes proliferation of ER membranes (Fig-
ure S5B) without concomitant upregulation of chaperones or
translocons (Figure S5C) [36]. Indeed, in an opi1D background,
oligomycin resistance was restored to an emc7D strain (Fig-
ure 5D), and synthesis of Yor1-DF was rescued (Figure 5E). ER
expansion did not alter ERAD efficacy, as monitored by CPY*
degradation (Figure S5D). Thus, expansion of the ER by approx-
imately 50% [36] creates permissive conditions in which Yor1-
DF biogenesis defects are reversed, perhaps by reducing
encounters between ribosomes engaged in synthesis.
Given the apparent importance of ribosome abundance in
Yor1-DF synthesis, we next examined translation initiation as a
potential point of regulation. Deletion of Tif4631, eIF-4G in mam-
mals, was a deletion suppressor [14], meaning that absence of
this initiation factor improved the functionality of Yor1-DF (Fig-
ure S3; Figure 5F). Conversely, deletion of Eap1, a 4E-binding pro-
tein that negatively regulates initiation, was a deletion enhancer,
causing reduced Yor1-DF function (Figure S3; Figures 5F and
5G). Both phenotypes are consistent with ribosome density on
the mRNA influencing Yor1-DF biogenesis; reduced initiation
should diminish ribosome density, whereas absence of a negative
regulator of initiation would increase ribosome density and thus
potential collisions. Pulse labeling of Yor1-DF in the eap1D strain
revealed reduced synthesis in comparison to synthesis in wild-
type cells, with mRNA levels unchanged (Figure 5H). Reducing
ribosome abundance by deletion ofRRP6 partially reversed oligo-
mycin sensitivity associated with loss of Eap1 (Figure 5G). The
eap1D rrp6D double mutant had reduced ribosome abundance,
in particular in the polysome fraction (Figure S5E). Thus, Eap1
seems to act as a negative regulator of Yor1 initiation; lack of
Eap1 causes overloading of Yor1 mRNA with ribosomes that is
detrimental, but reducing ribosome abundance reverses this ef-
fect. Active management of translation initiation, by Eap1 and
other factors, could permit a dynamic response to collision
events. Such translational tuning has previously been proposed
to act on human CFTR to promote nascent protein folding [37].
Figure 5. Translation Initiation as a Point of
Regulation of Yor1-DF Biogenesis
(A) Cartoon depicting ER-engaged ribosomes
(blue) synthesizing a polytopic membrane protein,
with hydrophobic TMDs (red) causing transient
stalls (brackets). In the absence of productive
folding or EMC function, stalls trigger ribosome
collisions (red spot) and RQC.
(B) Yor1-DF(HA) synthesis was measured in
emc7D strains where the ribosomal subunits indi-
cated were unable to be ubiquitinated. In this
experiment, incorporation was normalized to an
isogenic emc7D strain.
(C) Deletion of RRP6 rescued oligomycin sensi-
tivity of an emc7D strain, consistent with ribosome
abundance as a factor in EMC-mediated synthesis
defects.
(D) Deletion ofOPI1 reversed oligomycin sensitivity
of the emc7D strain.
(E) Metabolic labeling of Yor1-DF(HA) in the strains
indicated was quantified at t = 10 and normalized
to WT. Deletion of OPI1 reversed the synthesis
defect associated with EMC7 deletion.
(F) Cartoon of factors that regulate initiation. Cdc33
(eIF4E) is essential in yeast and thus was not
accessible to genetic analysis. Tif4631 (green) was
a deletion suppressor; Eap1 (eIF4E-BP) was a
deletion enhancer.
(G) Deletion of EAP1 causes oligomycin sensi-
tivity, which is reversed by additional loss of
RRP6.
(H) Metabolic labeling of the eap1D strain ex-
pressing Yor1-DF(HA) was quantified at t = 10 and
normalized to WT (left). Steady-state mRNA
levels were measured in the same strains by
qPCR, with Ct values normalized to actin and the
eap1D strain normalized to WT; each point represents a biological replicate comprising three technical replicates (right).
Statistical analyses used an unpaired Student’s t test; error bars depict SD. See also Figures S3 and S5.
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an important factor in Yor1 synthesis yield, but the broader
physiological relevance of ribosome density in multi-pass
membrane-protein biogenesis remained unclear. We therefore
considered whether translational tuning of membrane proteins
occurs across the yeast transcriptome. We quantified transla-
tion efficiency (TE), defined as ribosome abundance along a
message, from published ribosome profiling data [38] by calcu-
lating the ratio of ribosome-protected fragments to RNA-seq
reads [38] and separated the data into cytosolic and secreted
proteins. Secretome proteins exhibited lower TE than did cyto-
solic proteins, indicative of reduced ribosome occupancy (Fig-
ure S6A). Because ER targeting and/or translocation might
broadly impact TE, we narrowed our focus to secretome pro-
teins. We reasoned that polytopic membrane proteins, with
complex folding trajectories, might have evolved lower ribo-
some occupancy to minimize the potential for problematic
stalls. Comparing single TMD-containing proteins (excluding
tail-anchored proteins) and polytopic proteins (defined as >4
TMDs), we observed reduced TE associated with polytopic
proteins (Figure 6A). Moreover, dividing the polytopic group
into 4–6 TMD and >10 TMD subgroups revealed that TE
decreased with increasing TMD number (Figure 6A, right
panel). Within the >10 TMD group, putative EMC clients werefound with both ‘‘high’’ and ‘‘low’’ TE values (Figure 6A, anno-
tated in blue), suggesting that EMC dependence does not uni-
versally reflect low TE. Of note, Yor1 was among the lowest TE-
scoring proteins, consistent with its sensitivity to ribosome
abundance. The cohort of low-TE proteins also contained
non-EMC clients encompassing ion channels and solute car-
riers (Figure 6A, annotated in gray).
To rule out protein abundance effects as a confounding influ-
ence on TE, we extracted protein abundance data for each pro-
tein (PaxDB) and separated the polytopic proteins into low,
medium, and high abundances. As expected, TE distribution
broadly correlated with abundance, with low abundance pro-
teins generally having lower TE (Figure S6B). However,
comparing abundance of 4–6 TMD proteins to that of >10
TMD proteins showed no difference in the distribution of TE
(Figure 6B), suggesting that abundance effects alone cannot
explain the observed difference in TE. Moreover, when pro-
teins were separated by abundance, we observed reduced
TE in the >10 TMD category in comparison to the 4–6 TMD
category regardless of the abundance category (Figure 6C).
ORF length can also impact ribosome occupancy, with longer
ORFs having less ribosome density [41], and indeed polytopic
membrane proteins tended to be longer than other classes (Fig-
ure S6C). To rule out length effects on TE, we compared the TECurrent Biology 30, 1–11, March 9, 2020 7
Figure 6. Polytopic Membrane Proteins
Have Low Translation Efficiency
(A) Translation efficiency (TE) was calculated from
ribosome profiling data [38] and proteins sepa-
rated into different categories on the basis of
published classifications [39, 40]. Proteins with
single TMDs and polytopic TMDs had lower TE
than cytosolic proteins. Further separation of the
polytopic group into few (4–6 TMDs) and many
(>10 TMDs) further revealed reduced TE as TMD
number increased. EMC clients within the >10
TMD set are indicated by colored circles. Select
non-EMC clients (gray circles) are also indicated.
(B) To rule out TE effects caused by protein
abundance, we separated the polytopic group into
low-, medium-, and high-abundance classes. No
significant differences between protein abundance
(ppm) were observed between the 4–6 and >10
TMD classes, suggesting that abundance alone
cannot account for observed TE effects.
(C) Separating low- and high-abundance proteins
into 4–6 and >10 TMD classes; the observed
reduction in TE for >10 TMD proteins was still
observed.
(D) To rule out length effects, analysis as described
in (A) was restricted to proteins 200–2,000 amino
acids long, revealing reduced TE for polytopic
membrane proteins.
In all cases, statistical analyses were Mann-Whit-
ney tests, and error bars represent SD. See also
Figure S6.
Please cite this article in press as: Lakshminarayan et al., Pre-emptive Quality Control of a Misfolded Membrane Protein by Ribosome-Driven Effects,
Current Biology (2020), https://doi.org/10.1016/j.cub.2019.12.060for cytosolic, single-pass, and polytopic transmembrane (TM)
proteins for proteins between 200 and 2,000 amino acids. This
size window was chosen because both single-pass and poly-
topic protein groups had similar frequency distributions in this
range (Figure S6D). Length-corrected proteins still showed
reduced TE, both for single-pass TM proteins in relation to cyto-
solic proteins and for polytopic proteins (Figure 6D). To ensure
that comparisons between groups were meaningful, we plotted
effect size for both whole proteome and length-corrected ana-
lyses (Figure S6E) and observed that restricting the analysis to
a narrow length window reduced the effect size for cytosolic
comparisons, but for the critical single-pass TM proteins versus
polytopic membrane-protein groups, the differential effect was
comparable, lending confidence to our analysis. In light of our
genetic, biochemical, and bioinformatic data, we propose that
low TE for multi-pass polytopic membrane proteins reflects
evolutionary pressure to slow translation initiation and/or
elongation to permit correct targeting, TMD insertion, and TMD
folding [42].8 Current Biology 30, 1–11, March 9, 2020DISCUSSION
Protein misfolding in the ER has long
been recognized as an important point
of cellular quality control, enacted at a
systems level by the unfolded protein
response (UPR) and through the direct
actions of ERAD machinery. Here, we
describe an additional layer of qualitycontrol that acts early during protein synthesis to prevent the
accumulation of aberrant proteins. In the case of Yor1, we
find that this pre-emptive quality control is exacerbated by
deletion of the EMC, a TMD insertase [2, 16], which might
also function as a chaperone [8]. Moreover, specific defects
in the canonical translocon, Sec61, also confer reduced Yor1
synthesis, indicative of pre-emptive quality control. Our data
don’t speak to the molecular function of the EMC, a conserved
complex in eukaryotes [15, 43, 44], implicated in diverse
cellular functions including lipid transfer between ER and
mitochondria [45], viral intoxication [46], membrane-protein
insertion [2, 16], and membrane-protein folding [8, 47].
However, our findings, which show that loss of EMC pheno-
copies specific dysfunction of Sec61, are consistent with a
role for EMC in TMD handling at early stages of synthesis.
Importantly, the topology of Yor1 is distinct from that of
GPCRs, where the mammalian EMC establishes the correct
orientation of the first TMD [16]. It is possible that the EMC is
responsible for insertion of downstream helices in Yor1, most
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insertion of specific poorly hydrophobic TMDs.
We propose that when ER insertion and/or folding of nascent
TMDs is impaired, ER-engaged ribosomes become stalled, trig-
gering downstream quality-control pathways. Recent structural
data on ribosomes stalled by a small molecule, PF846, which
triggers selective translational arrest of several secretory
proteins [48], suggest a possiblemechanism. In PF846-stalled ri-
bosomes, the hydrophobic nascent chain interacts with the
ribosomal exit tunnel, creating a kinked structure that impairs
elongation [49]. We propose that Yor1 TMDs might be prone to
similar hydrophobic interactions within the exit tunnel that can
impede elongation. Correct folding and/or the action of the
EMC could provide a pulling force to prevent or overcome
such transient stalls, analogous to mechanisms that relieve
bacterial stalling signals [50]. Loss of EMC, or Sec61 dysfunc-
tion, combined with specific misfolding lesions would result in
prolonged stalls that in turn trigger ribosome collisions and
reduced protein synthesis. Analysis of ribosome-protected frag-
ments along aberrant Yor1 mRNAs will be required to determine
the existence and nature of ribosome stalls under different
conditions.
Ribosome collisions create a specific disome interface [23, 24]
that recruits ubiquitination machinery to initiate RQC. Several
early-acting RQC components participate in Yor1-DF quality con-
trol, whereas deletion of the RQC-associated E3 ligase Ltn1 had
minimal effect, perhaps indicating partial redundancy with ERAD
machinery, which also had relatively modest effects. Understand-
ing the precise, and probably diverse, roles of the ubiquitin/pro-
teasome system in this pathway will require more specific assays
than are currently available for Yor1-DF. The nature of the Yor1
stalls remain to be determined and could be heterogeneous, as
was observed for PF846-induced stalls [49]. One puzzling aspect
of the pre-emptive QC pathway that we describe is the difference
in mRNA abundance depending on the trigger for synthesis de-
fects. In the case of Sec61 dysfunction, Yor1-DF mRNA levels
were reduced dependent on Hel2, suggesting RNA cleavage
and degradation is triggered upon RQC. In contrast, we saw no
evidence for mRNA degradation upon loss of EMC function.
This difference could reflect the distinct functions of EMC and
Sec61, or perhaps separate RQC pathways that differentially
engage mRNA decay machineries.
Our observations that differences in ribosome function and
abundance modulate the synthesis of Yor1-DF in the context
of aberrant ER membrane insertion led us to consider whether
cells might actively manage translation of complex membrane
proteins. Indeed, previous analyses identified reduced TE asso-
ciated with signal recognition particle (SRP) binding, caused by
reduced codon optimality that slows elongation to promote
SRP binding [51]. Our TE analysis suggests that similar effects
might operatemore broadly, particularly for polytopicmembrane
proteins that could represent a folding challenge. Whether the
global reduction in TE that we observe can be explained by hot-
spots of reduced translation caused by poor codon optimality or
by active management of translation initiation remains to be
tested. Nonetheless, it seems likely that pre-emptive quality con-
trol will be important for biogenesis of many polytopicmembrane
proteins. Indeed, rescue of CFTR-DF by knockdown of mRNA
degradation machinery and by reduction in translation rates issuggestive of such an effect [21, 22]. Moreover, depletion of initi-
ation factors also rescues CFTR-DF, yielding increased mRNA,
increased synthesis, and improved folding yield [52], suggesting
that reducing ribosome abundance along the CFTR mRNA simi-
larly improves synthesis yield. Finally, ‘‘translational tuning,’’
whereby ribosome effects and codon usage modulate transla-
tion rates and folding trajectories, is important for folding of the
CFTR cytosolic domains [37]. Thus, pre-emptive quality control
might be a universal protective mechanism that prevents accu-
mulation of aggregate-prone TMDs and safeguards the
secretome.STAR+METHODS
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Antibodies
Ani-HA, mouse monoclonal Biolegend Cat# MMS-101R
Anti-Sec22, rabbit polyclonal Miller Lab N/A
Anti-Gap1, rabbit polyclonal Schekman Lab N/A
Anti- Sec61, rabbit polyclonal Schekman Lab N/A
p-eIF2a (S52), rabbit polyclonal Invitrogen Cat# 44-728G
Chemicals, Peptides, and Recombinant Proteins
Cycloheximide Sigma Aldrich Cat# C7698
Protein A Sepharose 4 Fast Flow GE Healthcare Cat# 17-5280-01
Protein G Sepharose 4 Fast Flow GE Healthcare Cat# 17-0618-01
Oligomycin Generon Cat# A5588
RNase OUT recombinant inhibitor Invitrogen Cat# 10777019
TRIzol Reagent Invitrogen Cat# 15596026
Trypsin Sigma Aldrich Cat# T9935
Trypsin inhibitor Sigma Aldrich Cat# T9003
EasyTag EXPRESS35S Protein Labeling Mix Perkin Elmer Cat# NEG772002MC
TRAN35S-LABEL, Metabolic Labeling Reagent MP Biomedicals Cat# MP015100614 (discontinued)
Critical Commercial Assays
iScript cDNA synthesis kit BioRad Cat# 1708891
KAPA Sybr fast universal kit Sigma Aldrich Cat# KK4601
PureLink Dnase Invitrogen Cat# 12185010
PureLink RNA Minikit Invitrogen Cat# 12183025
QuikChange Lightning Site-Directed Mutagenesis Kit Agilent Cat# 210519
Experimental Models: Organisms/Strains
Mat-a deletion collection Dharmacon Cat#YSC1053
MATa his3D1, leu2 D0, met15D0, ura3D0, yor1::KANMX Open biosystems LMY094
MATa can1::STE2pr-Sp_His5, his3D1, leu2D0, met15D0,
ura3D0, lypD1, yor1D::NATMX
Miller lab RLY122
MATa can1::STE2pr-Sp_His5, his3D1, leu2D0, ura3D0,
lypD1, yor1::NATMX, emc7::KANMX
This paper RLY23
MATa can1::STE2pr-Sp_His5, his3D1, leu2D0, ura3D0,
lypD1, yor1::NATMX, emc1::KANMX
This paper RLY25
MATa can1::STE2pr-Sp_His5, his3D1, leu2D0, ura3D0,
lypD1, yor1::NATMX, emc2::KANMX
This paper RLY26
MATa can1::STE2pr-Sp_His5, his3D1, leu2D0, ura3D0,
lypD1, yor1::NATMX, emc3::KANMX
This paper RLY27
MATa can1::STE2pr-Sp_His5, his3D1, leu2D0, ura3D0,
lypD1, yor1::NATMX, emc4::KANMX
This paper RLY28
MATa can1::STE2pr-Sp_His5, his3D1, leu2D0, ura3D0,
lypD1, yor1::NATMX, emc5::KANMX
This paper RLY29
MATa can1::STE2pr-Sp_His5, his3D1, leu2D0, ura3D0,
lypD1, yor1::NATMX, emc16::KANMX
This paper RLY30
MATa can1::STE2pr-Sp_His5, his3D1, leu2D0, ura3D0,
lypD1, yor1::NATMX, emc6::KANMX, emc2::LEU2
This paper RLY71
MATa can1::STE2pr-Sp_His5, his3D1, leu2D0, ura3D0,
lypD1, yor1::NATMX, rpl12a::KANMX
This paper RLY35
(Continued on next page)
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MATa can1::STE2pr-Sp_His5, his3D1, leu2D0, ura3D0,
lypD1, yor1::NATMX, rrp6::KANMX
This paper RLY13
MATa can1::STE2pr-Sp_His5, his3D1, leu2D0, ura3D0,
lypD1, yor1::NATMX, emc7::KANMX, rrp6::LEU2
This paper RLY187
MATa can1::STE2pr-Sp_His5, his3D1, leu2D0, ura3D0,
lypD1, yor1::NATMX, emc7::KANMX, rpl12a:LEU2
This paper RLY90
MATa can1::STE2pr-Sp_His5, his3D1, leu2D0, ura3D0,
lypD1, yor1::NATMX, emc7::KANMX, ltn1::LEU2
This paper RLY1
MATa can1::STE2pr-Sp_His5, his3D1, leu2D0, ura3D0,
lypD1, yor1::NATMX, emc7::KANMX, cue1::LEU2
This paper RLY93
MATa can1::STE2pr-Sp_His5, his3D1, leu2D0, ura3D0,
lypD1, yor1::NATMX, emc7::KANMX, rpn4::LEU2
This paper RLY84
MATa can1::STE2pr-Sp_His5, his3D1, leu2D0, ura3D0,
lypD1, yor1::NATMX, emc7::KANMX, rps0::LEU2
This paper RLY119
MATa can1::STE2pr-Sp_His5, his3D1, leu2D0, ura3D0,
lypD1, yor1::NATMX, emc7::KANMX, rps9::LEU2
This paper RLY120
MATa his3D1, leu2 D0, met15D0, ura3D0, opi1::KANMX
yor1::NATMX
This paper YBP171
MATa his3D1, leu2 D0, met15D0, ura3D0, opi1::KANMX
yor1::NATMX emc7::HPHMX
This paper YBP172
MATa can1::STE2pr-Sp_His5, his3D1, leu2D0, met15D0,
ura3D0, lypD1, yor1D::NATMX emc7::HPH
This paper YBP131
MATa trp1-1, ade2, leu 2-3,112, ura3, his3-11
ssh1::KANMX4 sec61::HIS3
[53] RGY400
MATa trp1-1, ade2, leu 2-3,112, ura3, his3-11
ssh1::KANMX4 sec61::HIS3 emc7::NATMX
This paper YBP225
MATa trp1-1, ade2, leu 2-3,112, ura3, his3-11
ssh1::KANMX4 sec61::HIS3 emc7::NATMX hel2::TRP
This paper YBP197
W303-1a background rps20D::NATMX4, p414GPDp-
RPS20-CYC1t
[29] N/A
W303-1a background rps20D::NATMX4, p414GPDp-
RPS20-CYC1t emc7::LEU2
This paper YBP218
W303-1a background rps20D::NATMX4, p414GPDp-
rps20 K6R K8R-CYC1t
[29] N/A
W303-1a background rps20D::NATMX4, p414GPDp-
rps20 K6R K8R-CYC1t emc7::LEU2
This paper YBP217
W303-1a background rps3D::NATMX4, p414GPDp-
RPS3-CYC1t
[29] N/A
W303-1a background rps3D::NATMX4, p414GPDp-
RPS3-CYC1t emc7::LEU2
This paper YBP220
W303-1a background rps3D::NATMX4, p414GPDp-rps3
K212R-CYC1t
[29] N/A
W303-1a background rps3D::NATMX4, p414GPDp-rps3
K212R-CYC1t emc7::LEU2
This paper YBP222
MATa can1::STE2pr-Sp_His5, his3D1, leu2D0, ura3D0,
lypD1, yor1::NATMX, rrp6::KANMX eap1::LEU2
This paper YIB01
MATa can1::STE2pr-Sp_His5, his3D1, leu2D0, met15D0,
ura3D0, lypD1, yor1D::NATMX, SEC63-sfGFP::HIS3
This paper NGY528
MATa, leu2 D0, met15D0, ura3D0, yor1::NATMX,
emc7::HPHMX, SEC63-sfGFP::HIS3
This paper NGY529
MATa, leu2 D0, met15D0, ura3D0, yor1::NATMX,
opi1::KANMX, SEC63-sfGFP::HIS3
This paper NGY530
MATa, leu2 D0, met15D0, ura3D0, yor1::NATMX,
opi1::KANMX, emc7::HPHMX, SEC63-sfGFP::HIS3
This paper NGY531
(Continued on next page)
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MATa can1::STE2pr-Sp_His5, his3D1, leu2D0, ura3D0,
lypD1, yor1::NATMX, emc7::KANMX, hel2::LEU2
This paper YIB037
MATa can1::STE2pr-Sp_His5, his3D1, leu2D0, ura3D0,
lypD1, yor1::NATMX, emc7::KANMX, dom34::LEU2
This paper YIB038
MATa can1::STE2pr-Sp_His5, his3D1, leu2D0, ura3D0,
lypD1, yor1::NATMX, emc7::KANMX, slh1::LEU2
This paper YIB039
Oligonucleotides
AATTATGGGATGCATTGGTGAGAGG (qPCR Yor1 fw) IDT OIB204
TCACCTAAGGAGAAATTGGAGCCC (qPCR Yor1 rv) IDT OIB205
GGTTTGGAATCTGCCGGTATTG (qPCR Act1 fw) IDT OIB210
CAAAGCGGTGATTTCCTTTTGC (qPCR Act1 rv) IDT OIB211
Recombinant DNA
pRS316(URA) YOR1-HA [12] pEAE83
DF670 and R1116T mutations in pEAE83 [14] LMB287
G278R (Yor1 G278R) mutation in pEAE83 [18] spQC35
R387G (Yor1R387G) mutation in pEAE83 [19] spQC36
I1084P (Yor1 I1084P) mutation in pEAE83 [18] spQC39
F270S and R1168M mutations in LMB287 [18] JH079
R1116T (Yor1 I1084P, R1116T) mutation in spQC39 This paper ICL4RT
D71AE73A (Yor1D71A, E73A) mutation in pEAE83 [13] pLM31
pRS315(LEU) SEC61 [34] pBW11
pRS315(LEU) sec61-R275E/R406E [53] N/A
pRS315(LEU) sec61-N302L [34] pEM634
pRS315(LEU) sec61-Q129N [34] pEM629
pRS315(LEU) sec61-R275E/K464E/K470E [33] pEM905
pRS316(URA) YOR1-GFP [12] pEAE93
pRS316(URA) Yor1-DF670-GFP [13] LMB037
pRS316(URA) Ste6-166-HA [54] pSM1083
Yep(URA) Ycf1DF713-GFP Susan Michaelis pSM1755
pRS316(URA) CPY*-HA Peter Walter pCP258
pFA6-LEU [55] LMB138
pFA6a-KanMX6 [55] LMB298
pFA6a-GFP(S65T)-HIS3MX6 [55] LMB303
Software and Algorithms
Nikon NIS Elements software Nikon RRID: SCR_014329
Andor iQ3 software Oxford Instruments RRID: SCR_014461
ImageQuant software GE Healthcare RRID: SCR_014246
Prism v.8 GraphPad RRID: SCR_002798
ImageJ (FiJi) NIH RRID: SCR_002285
QuantStudio Real-Time PCR Software v1.3 Thermo Fisher https://www.thermofisher.com/uk/en/home/life-science/
pcr/real-time-pcr/real-time-pcr-instruments/
quantstudio-qpcr-product-portfolio.html
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact,
Elizabeth Miller (emiller@mrc-lmb.cam.ac.uk). Yeast strains and plasmids generated in this study have not been deposited in
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Saccharomyces cerevisiae strains used in the study are listed in the Key Resources Table. Cultures were grown at 30C in standard
rich medium (YPD: 1% yeast extract, 2% peptone, and 2% glucose) or synthetic complete medium (SC: 0.67% yeast nitrogen base
and 2% glucose supplemented with amino acids as needed).
METHOD DETAILS
Strain construction
The query strain (RLY122) used to make double mutants was made by Silvere Pagant using PCR-mediated homologous recombi-
nation to knock out the YOR1 gene (MATa can1::STE2pr-Sp_His5, his3D1, leu2D0, met15D0, ura3D0, lypD1, yor1D::NATMX). YOR1/
EMC doublemutants and various YOR1/EMC7/xxx triple mutants were created by the synthetic genetic array (SGA)method [56]. The
query strain was mated to different deletion mutant strains from the MATa deletion collection (Dharmacon). Strains were mated on
YPD plates overnight, followed by diploid selection on YPD +G418 +NAT. Strains were then sporulated for a week at 25C before two
rounds of haploid double/triple mutant selection [56]. The resulting strains were then transformed with different YOR1 constructs for
phenotypic analysis and labeling experiments. The sec61D ssh1D emc7D triple mutant strain was made by crossing and tetrad
dissection to avoid suppression effects, then transformed with various Yor1 plasmids for labeling experiments. Additional mutants
were made by PCR-mediated homologous recombination using Longtine cassettes with 40 bp homology arms immediately up-
stream and downstream of the insertion [55].
Plasmids
The plasmids used in this study are listed in the Key Resources Table. pEAE83 bearing YOR1-HA in pRS316 was a gift from Scott
Moye-Rowley (University of Iowa). This plasmid was the basis for site-directed mutagenesis by using QuikChange mutagenesis
(Stratagene, La Jolla, CA) to obtain various hemagglutinin (HA)-tagged Yor1 mutants [18]. To facilitate genetic screening
approaches, we use a gain-of-function allele, R1116T, which confers increased drug clearance activity to both wild-type and mis-
folded forms of the protein, yet doesn’t impact folding or biogenesis. In this and our previous study [14], we use Yor1-DF670/
R1116T for both phenotypic and biochemical analyses, but refer to the protein as Yor1-DF for simplicity.
Oligomycin sensitivity assay
Strains were grown to saturation in SC -ura medium overnight at 30C. 10-fold serial dilutions were made in 96 well plates
before spotting onto YPEG (1% yeast extract, 2% peptone, 3% ethanol, 3% glycerol) plates containing different concentrations
of oligomycin (0, 0.2, 0.6 mg/mL). Plates were scanned at day 4 or day 5 after spotting and growth at 30C.
Metabolic labeling
Cells were grown to mid-log phase (A600 0.5) in complete synthetic medium; a total of 8 A600 cells were harvested, washed and
resuspended in SC medium (2ml) lacking Met/Cys, and incubated at 30C for 15 min while gently shaking. Nascent proteins were
labeled at 30C for different times (2.5, 5, 10, 15 min) by adding 30 mCi of 35S-Met/Cys (MP Biomedicals or Perkin Elmer)/A600 cells
(24 mL of label/reaction). 500 mL of cells were harvested per strain at each time point using a pre-set timer and were transferred to
chilled tubes containing a final concentration of 20mM NaN3. Cells were washed once with 20mM NaN3 and resuspended in
100 mL of 1% SDS. Cells were disrupted by glass bead lysis (15 min, 4C), heated to 55C for 5 min, and centrifuged at low speed
(500 g) for 30 s. Lysates were diluted with 5 volumes of immunoprecipitation buffer (50 mM Tris, pH 7.5, 160mM NaCl, 1% Triton
X-100, and 2mMNaN3), and cleared by centrifugation at 13,000 rpm for 5 min. Proteins were immunoprecipitated using monoclonal
anti-HA antibodies, precoupled to protein G-Sepharose beads (GE Healthcare), or polyclonal antibodies against Sec22 or Gap1
precoupled to protein A-Sepharose beads (GE Healthcare). Immune complexes were separated by SDS-PAGE and analyzed by
phosphorimaging analysis using a Typhoon PhosphorImager (GE Healthcare). Incorporation were quantified using ImageQuant
(GE Healthcare) or FiJi (NIH) software.
Protein aggregation assay
Wild-type and emc7D strains were grown to mid-log phase in complete synthetic medium; cells were harvested, washed and resus-
pended in SC medium lacking Met/Cys, and incubated at 30C for 15 min while gently shaking. Nascent proteins were labeled at
30C for 10min with 30 mCi of TRAN35S-Label (MP Biomedicals)/A600 cells. For separation into soluble and insoluble fractions, cells
were harvested and washed with 20mM NaN3 and incubated on ice for 5 min. Spheroplasts were prepared by treating cells initially
with an alkaline buffer (100mM Tris pH9.4, 10mM DTT, 100mM NaN3) for 10 min at room temperature followed by treatment with
lyticase in spheroplasting buffer (10mM Tris pH7.4, 0.7M sorbitol, 1mM DTT, 20mM NaN3) for 25 min at 30
C. Spheroplasts were
then collected, resuspended in 50mL hypo-osmotic lysis buffer (20mM HEPES pH6.8, 0.4M sorbitol, 150mM KOAc, 2mM Mg
(OAc)2, 0.5mM EGTA) and frozen at 80C. Frozen cell lysates were thawed, and subjected to centrifugation (15,000 rpm, 5 min.
4C). The supernatant corresponding to the soluble fraction was removed and mixed with an equal volume of 2X SDS sample buffer,
and the insoluble pellet was resuspended in 100mL of 1X SDS sample buffer before loading on SDS-PAGE and PhosphorImage
analysis as described above.Current Biology 30, 1–11.e1–e5, March 9, 2020 e4
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Cells were grown tomid-log phase in complete syntheticmedium; a total of 5 A600 cells were harvested, washed and resuspended in
SC medium lacking Met/Cys, and incubated at 30C for 15 min while gently shaking. Cells were metabolically labeled at 30C for
10 min with 60 mCi of TRAN35S-Label (MP Biomedicals)/A600 cells. Cells were harvested and washed with 20mM NaN3 and incu-
bated on ice for 5 min. Spheroplasts were prepared by treating cells initially with an alkaline buffer (100mM Tris pH9.4, 10mM DTT,
100mM NaN3) for 10 min at room temperature followed by treatment with lyticase in spheroplasting buffer (10mM Tris pH7.4, 0.7M
sorbitol, 1mM DTT, 20mM NaN3) for 25 min at 30
C. Spheroplasts were then washed in lysis buffer (20mM HEPES pH6.8, 0.4M sor-
bitol, 150mM KOAc, 2mMMg (OAc)2, 0.5mM EGTA) and were frozen at 80C. The following day, spheroplasts were thawed on ice
andwashed in low-acetate B88 buffer (20mMHEPESpH6.8, 250mMsorbitol, 50mMKOAc, 5mMMg(OAc)2) followed by twowashes
with B88 (20mMHEPES pH 6.8, 250mM sorbitol, 150nM KOAc, 5mMMg(OAc)2). Lysed cells were resuspended in 100 mL B88 buffer
and split into four 25 mL reactions per strain. Each reaction was treated with a final concentration of 0, 25, 50, 100 ng/ml trypsin for
10 min on ice. Digestion was terminated by addition of soybean trypsin inhibitor to all reactions followed by incubation on ice for
15 min and by two washes with B88. After solubilization with 1% SDS, spheroplasts were disrupted by glass bead lysis and heated
at 55C for 5 min. The resulting protein extracts were diluted with 5 volumes of immunoprecipitation buffer (50 mM Tris, pH 7.5,
160mM NaCl, 1% Triton X-100, and 2mM NaN3), and cleared by centrifugation. Yor1 fragments were immunoprecipitated from
the cleared supernatant and analyzed by SDS-PAGE and PhosphorImage analysis as described above.
GFP Imaging
Imaging was performed on cells grown to mid-log phase at 30C in selective media. Images were taken on a Nikon TE2000 inverted
fluorescence microscope with a 100x/1.49NA oil immersion objective and an sCMOS camera and collected using the Nikon NIS
elements software. For imaging of cortical ER in the opi1D strains, images were taken on an Andor Revolution Spinning Disk micro-
scope with a 40x/1.3NA oil immersion objective and an EMCCD camera. Images from the mid and cortical sections of cells were
collected using Andor iQ3 software.
qPCR
Yeast cells in mid-log phase were collected and RNA extracted using PureLink RNA Minikit (Thermo Fisher) with Trizol reagent and
on-column DNase treatment according to themanufacturer’s protocol. Eluted RNAwas used to prepare cDNA using iScript (BioRad)
kits, according to the manufacturer’s protocol. qPCR was performed using KAPA Sybr Fast Universal kits on a Viia 7 Real Time PCR
system, with primers that amplify YOR1 and ACT1 in triplicate, along with appropriate controls. For each condition, three biological
replicates were performed. YOR1was quantified relative to ACT1 using a relative standard curve. The standard curve was generated
from pooled cDNA to make a highest standard concentration, with 100 as the assigned quantity. Five more standards were then
generated with a 5 fold dilution series. Each cDNA sample to be measured was diluted 10-fold to ensure transcript abundance
was within the range of the standard curve. The Ct from each sample was measured against the standard curve to find the assigned
quantity, and then the assigned quantity of YOR1 was divided by that of ACT1 to calculate the relative abundance, using the
QuantStudio Real Time PCR software (ThermoFisher).
Polysome profiling
Yeast cells inmid-log phase (OD600 0.5-0.6) were treatedwith 100ug/mL cycloheximide for 15min, then harvested and resuspended
in 400ml lysis buffer (20mM HEPES 7.4, 5mMMg(CH3COO)2, 50mM KCl, 100ug/mL cycloheximide) supplemented with 20ml RNase-
OUT (Thermo Fisher). Cells were disrupted by glass bead lysis for 10mins at 2000rpm and 4C, then the lysate was cleared by centri-
fugation for 1 min at 3200rpm and 4C, followed by 10min at 13000rpm and 4C. Extracts were frozen in liquid nitrogen and stored at
80C until use. 8 A260nm units of the lysate were loaded onto a linear 5% - 45% (w/v) sucrose gradient in polypropylene 143 95mm
centrifuge tubes and centrifuged for 2.5 h at 284,600 x g and 4C. Gradients were fractionated using an A¨KTAprime plus liquid chro-
matography system and a Brandel gradient fractionator with continuous UV monitoring (A254nm). The collected fractions were frozen
in liquid nitrogen and stored at 80C.
QUANTIFICATION AND STATISTICAL ANALYSES
For radiolabeling experiments, band intensity was measured using a Typhoon PhosphorImager (GE Healthcare) and quantified using
either ImageQuant (GE Helthcare) or ImageJ/FiJi (NIH) software. Statistical analyses were performed using GraphPad Prism software.
Plots were also generated using this software. Details of statistical tests for individual experiments can be found in the figure legends. In
general, n refers to independent biological replicates of a given experiment. Significance was defined as a p value less than 0.05.
DATA AND CODE AVAILABILITY
Translation efficiencywas calculated frompublished data [38]. TE for each genewith aminimumof 5 rpkmwas calculated as the ratio of
ribosome-protected footprints (RPF) to RNA-seq rpkm. Secretome proteinswere identified and classified/sorted using annotated data-
sets [39, 40]. Protein abundancewas downloaded frompax-db.org. Data generated for this analysis is available from the LeadContact.e5 Current Biology 30, 1–11.e1–e5, March 9, 2020
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Figure S1. Loss of EMC reduces Yor1-DF function. Related to Figure 1.  (A) Yeast strains deleted 
for YOR1 and the additional genes indicated were transformed with a plasmid expressing Yor1-
DF(HA) and grown overnight in SD -ura before serial dilution and spotting onto YPEG media (right 
panel) or YPEG supplemented with the oligomycin as indicated. Cells were incubated at 30ºC for 3-4 
days and plates imaged. Mutation of any of the EMC components reduced the oligomycin resistance 
associated with Yor1-DF expression. (B) Lysates from WT and emc7D strains expressing Yor1-DF or 
the functional ICL2 mutant (Yor1-R387G) were probed with antibodies against eIF2a and phosphor-
eIF2a. Neither condition yielded increased phosphorylation indicative of ISR activation. In contrast, 
pre-treatment of WT cells with rapamycin clearly induced eIF2a phosphorylation. 
  
 Figure S2. EMC loss doesn’t exacerbate ERAD, aggregation or misfolding. Related to Figure 3. 
(A) Strains deleted for YOR1 and either RPN4 or CUE1 were metabolically labeled and incorporation 
at t=10 relative to a WT strain was quantified. Both mutants showed reduced incorporation of Yor1-DF 
relative to WT. Statistical analysis was an unpaired Student’s t-test; error bars depict SD. (B) 
Radiolabeled cells were spheroplasted, gently lysed and subject to limited proteolysis before 
immunoprecipitation. No major differences in cleavage patterns were detected between WT and emc7D 
cells. (C) WT and emc7D cells subjected to metabolic labeling were spheroplasted and separated into 
insoluble (I) and soluble (S) fractions prior to SDS-PAGE and PhosphorImage analysis. No major 
differences in the soluble and insoluble fractions were apparent. (D) Yor1-GFP and Yor1-DF-GFP 
were expressed in WT and emc7D cells. No differences in intracellular puncta/aggregates were 
detected in the emc7D strain. Conversely, expression of Yor1-DF-GFP in a severe Sec61 targeting 
mutant resulted in strong punctate accumulation (see Figure 6B, middle panel). Scale bar is 5 µm.  
  
Figure S3. Genetic signatures of pre-emptive quality control: Translation-related proteins 
influence Yor1-DF function. Related to Figures 3 and 5. 
Heat map of interaction scores from a phenotypic screen for factors that influence Yor1-DF biogenesis 
[14]. The interaction score represents the change in lag-phase growth (L, the time to half-maximal 
growth measured in hours) of a mutant strain relative to the wild-type control on a given concentration 
of oligomycin. A negative value corresponds to improved growth relative to WT (ie. less lag and 
therefore faster growth). Darker blue corresponds to better growth (ie. stronger suppression of 
oligomycin sensitivity associated with Yor1-DF expression). Interaction scores for various classes of 
GO-enriched functional terms are shown, alongside the corresponding interaction scores for equivalent 
strains expressing WT Yor1. Additional hits relevant to Translation Initiation/Elongation and 
Ribosome-associated Quality Control are also included. 
 
  
 Figure S4. mRNA levels of Yor1 mutants in emc7D cells. Related to Figure 3.   
Steady state mRNA levels for the indicated YOR1 alleles were quantified by qPCR in WT and emc7D 
cells. CT values for each test sample were compared to a standard curve, then normalized to actin 
similarly measured according to a standard curve, and the relative levels in emc7D cells depicted 
relative to WT. Each biological replicate (individual data points) was analyzed in triplicate technical 
replicates; Statistical test was an unpaired Student’s t-test; error bars are SD. 
 
  
 
 
 
Figure S5. Ribosome dilution effects influence synthesis defects. Related to Figure 5.  
(A) Representative polysome profiles of lysates prepared from the indicated strains reveals that the 
rrp6D mutant contains reduced abundance of 60S, 80S and polysomes, as well as the appearance of 
“halfmers”, indicated by arrowheads. (B) ER morphology was examined using Sec63-sfGFP integrated 
into the genomic locus in the strains indicated. Confocal imaging of mid-cell and cortical planes 
revealed more abundant and sheet-like ER in the cortical ER in strains deleted for OPI1, as described 
previously [36]. (C) Steady state levels of Sec61 in the strains indicated were measured from whole-
cell lysates by immunoblotting using a Sec61-specific polyclonal antibody. No change in abundance 
was observed upon ER proliferation in the opi1D mutants. (D) Pulse-chase experiments of the model 
misfolded protein, CPY*-HA in the strains indicated revealed no change in ERAD associated with ER 
expansion upon loss of OPI1. n=3; error bars represent SD.  (E) Representative polysome profiles 
prepared from lysates of the indicated strains shows no major differences upon loss of EAP1, but 
reduced ribosome abundance upon additional loss of RRP6. 
 
  
 
Figure S6. Secreted proteins have reduced translation efficiency. Related to Figure 6.  
(A) Secretome proteins had significantly lower translation efficiency (TE) than cytosolic proteins. (B) 
Polytopic membrane proteins (>4 TMDs) were separated into low-, medium- and high-abundance 
classes based on PaxDB data. Higher-abundance proteins had higher TE. (C) Polypeptide length is 
plotted for different protein classes; polytopic membrane proteins (>4 TMDs) tend to be longer than 
cytosolic or single-pass TM proteins. (D) Length distribution of single-pass and polytopic membrane 
proteins were plotted to find a length window appropriate for comparison of length-controlled proteins. 
(E) Effect size was measured for the different comparisons indicated, either considering the entire 
proteome, or the length-controlled population. Statistical tests were all Mann-Whitney U tests and 
error bars represent SD. 
